Philip Harvey

Summary

Country: USA

Publications

  1. ncbi Outcomes to monitor when treating bipolar disorder or schizophrenia
    Philip D Harvey
    Department of Psychiatry, Mt. Sinai School of Medicine, New York, NY, USA
    J Clin Psychiatry 67:e06. 2006
  2. ncbi Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning
    Philip D Harvey
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Psychiatry 163:1918-25. 2006
  3. ncbi Impairment in functional capacity as an endophenotype candidate in severe mental illness
    Philip D Harvey
    To whom correspondence should be addressed tel 1 305 243 4094, fax 1 305 243 1619, E mail
    Schizophr Bull 38:1318-26. 2012
  4. ncbi Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches
    Philip D Harvey
    Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, 1120 North West 14th Street, Suite 1450, Miami, FL 33136, USA
    Psychiatr Clin North Am 35:683-98. 2012
  5. ncbi Clinical applications of neuropsychological assessment
    Philip D Harvey
    University of Miami Miller School of Medicine, Research Service, Bruce W Carter VA Medical Center, Miami, FL 33136, USA
    Dialogues Clin Neurosci 14:91-9. 2012
  6. ncbi Validating the measurement of real-world functional outcomes: phase I results of the VALERO study
    Philip D Harvey
    Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, FL 33136, USA
    Am J Psychiatry 168:1195-201. 2011
  7. ncbi The course of neuropsychological performance and functional capacity in older patients with schizophrenia: influences of previous history of long-term institutional stay
    Philip D Harvey
    Department of Psychiatry, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Biol Psychiatry 67:933-9. 2010
  8. ncbi Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, New York, NY 10029, USA
    Am J Psychiatry 162:110-7. 2005
  9. ncbi Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness
    Philip D Harvey
    Mt Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    Expert Opin Pharmacother 6:337-46. 2005
  10. ncbi Performance-based measures of functional skills: usefulness in clinical treatment studies
    Philip D Harvey
    Schizophr Bull 33:1138-48. 2007

Research Grants

  1. Course of Functional Deficits in Late-Life Schizophrenia
    Philip Harvey; Fiscal Year: 2007
  2. Validation of Measures of real-world outcome
    Philip Harvey; Fiscal Year: 2007
  3. Validation of Measures of real-world outcome
    Philip Harvey; Fiscal Year: 2009
  4. Validation of Measures of real-world outcome
    Philip D Harvey; Fiscal Year: 2010

Detail Information

Publications88

  1. ncbi Outcomes to monitor when treating bipolar disorder or schizophrenia
    Philip D Harvey
    Department of Psychiatry, Mt. Sinai School of Medicine, New York, NY, USA
    J Clin Psychiatry 67:e06. 2006
    ..The implications for the treatment of bipolar disorder stem from the ideology that underlies many of the studies in schizophrenia...
  2. ncbi Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning
    Philip D Harvey
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Psychiatry 163:1918-25. 2006
    ....
  3. ncbi Impairment in functional capacity as an endophenotype candidate in severe mental illness
    Philip D Harvey
    To whom correspondence should be addressed tel 1 305 243 4094, fax 1 305 243 1619, E mail
    Schizophr Bull 38:1318-26. 2012
    ....
  4. ncbi Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches
    Philip D Harvey
    Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, 1120 North West 14th Street, Suite 1450, Miami, FL 33136, USA
    Psychiatr Clin North Am 35:683-98. 2012
    ....
  5. ncbi Clinical applications of neuropsychological assessment
    Philip D Harvey
    University of Miami Miller School of Medicine, Research Service, Bruce W Carter VA Medical Center, Miami, FL 33136, USA
    Dialogues Clin Neurosci 14:91-9. 2012
    ....
  6. ncbi Validating the measurement of real-world functional outcomes: phase I results of the VALERO study
    Philip D Harvey
    Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, FL 33136, USA
    Am J Psychiatry 168:1195-201. 2011
    ....
  7. ncbi The course of neuropsychological performance and functional capacity in older patients with schizophrenia: influences of previous history of long-term institutional stay
    Philip D Harvey
    Department of Psychiatry, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Biol Psychiatry 67:933-9. 2010
    ..The present study examined older outpatients who varied in their lifetime history of long-term psychiatric inpatient stay...
  8. ncbi Stability of cognitive performance in older patients with schizophrenia: an 8-week test-retest study
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, New York, NY 10029, USA
    Am J Psychiatry 162:110-7. 2005
    ..There are several factors that could lead to spurious improvements in cognitive test scores, including practice effects and random test-retest errors...
  9. ncbi Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness
    Philip D Harvey
    Mt Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    Expert Opin Pharmacother 6:337-46. 2005
    ..Several issues remain to be addressed, including the efficacy of once-daily dosing, the need to take the medication with food, and the correct dosing strategy...
  10. ncbi Performance-based measures of functional skills: usefulness in clinical treatment studies
    Philip D Harvey
    Schizophr Bull 33:1138-48. 2007
    ....
  11. ncbi Pharmacological approaches to the management of cognitive dysfunction in schizophrenia
    Philip D Harvey
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
    Drugs 66:1465-73. 2006
    ..The mixed results of pharmacological interventions are most likely to be as a result of a combination of methodological flaws of many studies, poor outcome measures, dose administration effects and problems with the agents themselves...
  12. ncbi Dual-task information processing in schizotypal personality disorder: evidence of impaired processing capacity
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, New York, NY 10029, USA
    Neuropsychology 20:453-60. 2006
    ..The authors discuss the implications of these processing capacity limitations for understanding both the signature of cognitive impairment within the schizophrenia spectrum and general abnormalities in working memory...
  13. ncbi The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    Psychopharmacology (Berl) 187:356-63. 2006
    ..Thus, this study used a database from an existing clinical trial and examined the relationships between changes in clinical symptoms and cognitive deficits with several different strategies...
  14. ncbi Conference report: the Seventh Biennial Mt. Sinai Conference on Cognition in Schizophrenia
    Philip D Harvey
    Mt. Sinai School of Medicine, USA
    Schizophr Bull 31:895-7. 2005
  15. ncbi Neuropsychological normalization with long-term atypical antipsychotic treatment: results of a six-month randomized, double-blind comparison of ziprasidone vs. olanzapine
    Philip D Harvey
    Department of Psychiatry, Box 1229 Mount Sinai School of Medicine, New York, NY 10029, USA
    J Neuropsychiatry Clin Neurosci 18:54-63. 2006
    ....
  16. ncbi Negative symptoms and cognitive deficits: what is the nature of their relationship?
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, New York, NY, USA
    Schizophr Bull 32:250-8. 2006
    ....
  17. ncbi The validation of a caregiver assessment of dementia: the Dementia Severity Scale
    Philip D Harvey
    Mt Sinai School of Medicine, New York, New York 10029, USA
    Alzheimer Dis Assoc Disord 19:186-94. 2005
    ..The Dementia Severity Scale is designed to measure deficits in activities of daily living (ADL), behavioral disturbances, and the caregiver's perception of the patient's current cognitive abilities...
  18. ncbi Defining and achieving recovery from bipolar disorder
    Philip D Harvey
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Clin Psychiatry 67:14-8; discussion 36-42. 2006
    ....
  19. ncbi Cognition and aging in psychopathology: focus on schizophrenia and depression
    Philip D Harvey
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
    Annu Rev Clin Psychol 2:389-409. 2006
    ..We see cognitive changes as a possible commonality across persistent psychiatric disorders as well as healthy aging in late life...
  20. ncbi A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment
    Philip D Harvey
    Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30032, United States
    Schizophr Res 105:138-43. 2008
    ..This study compared the cognitive benefits of clozapine and ziprasidone in schizophrenia patients (n=130) with a history of either failure to respond to or intolerance of previous adequate antipsychotic treatments...
  21. ncbi The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment
    Philip D Harvey
    epartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Woodruff Memorial Building, 101 Woodruff Circle, Suite 4000, Atlanta, GA 30322, USA
    Bipolar Disord 10:900-6. 2008
    ..We hypothesized, consistent with recent studies of schizophrenia, that the factor structure after treatment would be similar to the structure of untreated symptoms at study baseline...
  22. ncbi Evaluation of dementia rating scales in Parkinson's disease dementia
    Philip D Harvey
    Emory University School of Medicine, 101 Woodruff Circle, Atlanta, GA 30322, USA
    Am J Alzheimers Dis Other Demen 25:142-8. 2010
    ..This supports the validity of previous results obtained with these measures in studies of patients with PDD...
  23. ncbi The factor structure of clinical symptoms in depressed inpatients with unipolar or bipolar spectrum disorders: a preliminary study
    Philip D Harvey
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Nerv Ment Dis 197:161-5. 2009
    ..Our results suggest that similar levels of symptom severity may have different underpinnings in the 2 groups and suggest that more comparative studies of symptoms in these 2 conditions may be useful...
  24. ncbi Reduction of functional disability with atypical antipsychotic treatment: a randomized long term comparison of ziprasidone and haloperidol
    Philip D Harvey
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
    Schizophr Res 115:24-9. 2009
    ..This study examined the process of development of "functional remission" in a long-term comparative double-blind study of haloperidol and the atypical antipsychotic medication ziprasidone...
  25. ncbi Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder
    Philip D Harvey
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Geriatr Psychiatry 18:820-9. 2003
    ..To examine the effects of risperidone and olanzapine on cognitive functioning in elderly patients with schizophrenia or schizoaffective disorder...
  26. ncbi The course of functional decline in geriatric patients with schizophrenia: cognitive-functional and clinical symptoms as determinants of change
    Philip D Harvey
    Mt Sinai School of Medicine, New York, NY 10029, USA
    Am J Geriatr Psychiatry 11:610-9. 2003
    ..Authors sought to use a cognitive assessment instrument validated for assessing low-functioning patients to broaden knowledge about the rate and correlates of functional decline...
  27. ncbi Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder
    Philip D Harvey
    Department of Psychiatry, Mount Sinai School of Medicine, Box 1229, New York, NY 10029, USA
    Psychopharmacology (Berl) 172:324-32. 2004
    ..Newer antipsychotic medications have been reported to enhance cognitive functioning in schizophrenia. Head to head studies with double-blind methods are still relatively few in number...
  28. ncbi Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel
    Feea R Leifker
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
    Schizophr Bull 37:334-43. 2011
    ....
  29. ncbi Commentary: Chickens and eggs; carts and horses: an outsider's perspective on the study of the early stages and potential prevention of psychosis and schizophrenia
    Philip D Harvey
    Mt. Sinai School of Medicine, New York, NY 10029, USA
    Schizophr Bull 29:845-9. 2003
  30. ncbi Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept?
    Philip D Harvey
    Schizophr Bull 35:300-6. 2009
    ....
  31. ncbi Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia
    Philip D Harvey
    Mt Sinai School of Medicine, New York University, 1425 Madison Avenue, Fourth Floor, New York, NY 10029, USA
    Schizophr Res 66:101-13. 2004
    ....
  32. ncbi Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness
    Philip D Harvey
    Mt Sinai School of Medicine, 1425 Madison Avenue, New York, N Y 10029, USA
    J Clin Psychiatry 65:361-72. 2004
    ..Thus, a much wider range of improvements, not widely produced by previous treatments, is required to take treatment for schizophrenia to a new level of effectiveness...
  33. ncbi Validity and stability of performance-based estimates of premorbid educational functioning in older patients with schizophrenia
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    J Clin Exp Neuropsychol 28:178-92. 2006
    ..The results of these two studies suggest that word-recognition reading skills are useful screening instruments to estimate premorbid functioning even in deteriorated patients with schizophrenia...
  34. ncbi Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms
    Christopher R Bowie
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Psychiatry 163:418-25. 2006
    ..Assessment of the ability to perform life skills under optimal conditions (i.e., assessment of functional capacity) has been proposed as a means to clarify these relationships...
  35. ncbi Six-year outcomes in first admission adolescent inpatients: clinical and cognitive characteristics at admission as predictors
    David L Pogge
    Department of Psychological Assessment, Four Winds Hospital, Katonah, NY, USA
    Psychiatry Res 160:47-54. 2008
    ..In contrast to psychosis, depression at follow-up was predicted by admission symptomatology, but not by cognitive deficits...
  36. ncbi Correlates of change in functional status of institutionalized geriatric schizophrenic patients: focus on medical comorbidity
    Joseph I Friedman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Am J Psychiatry 159:1388-94. 2002
    ..While cognitive impairment has proven to be a major predictor of overall functional deficit in schizophrenia, other potential factors, such as medical comorbidity, need to be considered...
  37. ncbi Relationship of the Brief UCSD Performance-based Skills Assessment (UPSA-B) to multiple indicators of functioning in people with schizophrenia and bipolar disorder
    Brent T Mausbach
    Department of Psychiatry, University of California at San Diego, San Diego, 9500 Gilman Drive, La Jolla, CA 92093 0680, USA
    Bipolar Disord 12:45-55. 2010
    ....
  38. ncbi Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial
    Richard S E Keefe
    Department of Psychiatry, John Umstead Hospital, Duke University Medical Center, Durham, NC 27710, USA
    Arch Gen Psychiatry 64:633-47. 2007
    ..The relative effect of the second-generation (atypical) antipsychotic drugs and older agents on neurocognition has not been comprehensively determined...
  39. ncbi Predicting schizophrenia patients' real-world behavior with specific neuropsychological and functional capacity measures
    Christopher R Bowie
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Biol Psychiatry 63:505-11. 2008
    ..This study examined the different predictive relationships between NP domains, functional competence, social competence, symptoms, and real-world behavior in domains of work skills, interpersonal relationships, and community activities...
  40. ncbi Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, New York, NY, USA
    J Clin Psychiatry 68:1186-94. 2007
    ..The primary objective of this double-blind study was to compare the effects of treatment initiation with risperidone and quetiapine on cognitive function in subjects with stable bipolar disorder...
  41. ncbi Neuropsychological and symptom predictors of aggression on the psychiatric inpatient service
    Mark Serper
    Department of Psychiatry, New York University School of Medicine, New York, NY, USA
    J Clin Exp Neuropsychol 30:700-9. 2008
    ....
  42. ncbi The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA
    Am J Psychiatry 163:426-32. 2006
    ..This study describes the reliability and validity of a new interview-based assessment of cognition, the Schizophrenia Cognition Rating Scale (SCoRS), that involves interviews with patients and informants...
  43. ncbi Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, Box 1229, New York, NY 10029, USA
    Psychopharmacology (Berl) 169:404-11. 2003
    ..The effects of risperidone and olanzapine on cognitive functioning in patients with schizophrenia were compared in a randomized, double-blind trial...
  44. ncbi Depressed mood and its functional correlates in institutionalized schizophrenia patients
    Nina Rieckmann
    Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY, 10029, USA
    Schizophr Res 77:179-87. 2005
    ..To determine the frequency of depressed mood in institutionalized schizophrenia patients and its association with illness-related and functional variables...
  45. ncbi Determinants of everyday outcomes in schizophrenia: the influences of cognitive impairment, functional capacity, and symptoms
    Feea R Leifker
    Emory University School of Medicine, Atlanta, GA 30322, USA
    Schizophr Res 115:82-7. 2009
    ..For social and everyday living outcomes, variance accounted for by the entire array of predictive variables was less than 40%, suggesting that other factors, such as social and cultural influences, are involved as well...
  46. ncbi The longitudinal course of thought disorder in geriatric patients with chronic schizophrenia
    Christopher R Bowie
    Department of Psychiatry, Mount Sinai School of Medicine, 1425 Madison Ave, 4th Floor, Box 1230, New York, NY 10029, USA
    Am J Psychiatry 162:793-5. 2005
    ..This study longitudinally assessed previously validated dimensions of thought disorder--verbal underproductivity and disconnection--in geriatric schizophrenia and replicated previous cross-sectional differences in communication disorders...
  47. ncbi A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial
    Stephen M Stahl
    Department of Psychiatry, University of California, San Diego, CA 92093 9116 A, USA
    J Clin Psychopharmacol 30:425-30. 2010
    ....
  48. ncbi Ziprasidone and cognition: the evolving story
    Philip D Harvey
    Department of Psychiatry, Mt Sinai School of Medicine, New York University, New York 10029, USA
    J Clin Psychiatry 64:33-9. 2003
    ..Improvement in cognitive function observed with ziprasidone may have implications for long-term patient outcomes...
  49. ncbi Depression in schizophrenia: methodological artifact or distinct feature of the illness?
    Eran Chemerinski
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    J Neuropsychiatry Clin Neurosci 20:431-40. 2008
    ..Thus, the evaluation of domains within the BDI-II provides a more pure and clinically-relevant assessment of depressed mood in schizophrenia than the use of this scale as a whole...
  50. ncbi Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders
    Abraham Reichenberg
    Department of Psychiatry, Emory University School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Schizophr Bull 35:1022-9. 2009
    ..NP normality in psychotic affective disorders has not been systematically studied...
  51. ncbi Cortical neuritic plaques and hippocampal neurofibrillary tangles are related to dementia severity in elderly schizophrenia patients
    Michael A Rapp
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10128, USA
    Schizophr Res 116:90-6. 2010
    ....
  52. ncbi The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, P O Box 3270, Durham, NC 27710, USA
    Schizophr Res 68:283-97. 2004
    ..76) and healthy controls (r=0.90). These psychometric properties make the BACS a promising tool for assessing cognition repeatedly in patients with schizophrenia, especially in clinical trials of cognitive enhancement...
  53. ncbi Communication abnormalities predict functional outcomes in chronic schizophrenia: differential associations with social and adaptive functions
    Christopher R Bowie
    Department of Psychiatry, Mount Sinai School of Medicine, 1425 Madison Ave, 4th Floor, Box 1230, New York, NY 10029, USA
    Schizophr Res 103:240-7. 2008
    ..In this chronically institutionalized sample, communication disorder was a stronger predictor of social, but not adaptive, outcomes than neurocognition or clinical symptoms...
  54. ncbi Reduced processing resource availability in schizotypal personality disorder: evidence from a dual-task CPT study
    Patrick J Moriarty
    Department of Psychiatry, Mt. Sinai School of Medicine, New York, NY 10029, USA
    J Clin Exp Neuropsychol 25:335-47. 2003
    ....
  55. ncbi The broad importance of cognitive impairments in aging-related disorders
    Philip D Harvey
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia
    Am J Geriatr Psychiatry 16:99-101. 2008
  56. ncbi Cognition in schizophrenia: impairments, determinants, and functional importance
    Christopher R Bowie
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Psychiatr Clin North Am 28:613-33, 626. 2005
    ..General psychopathology symptoms, such as depression and anxiety, may become important treatment targets as strategies are developed for translating cognitive enhancement to real-world functional performance...
  57. ncbi Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS)
    Richard S E Keefe
    Department of Psychiatry, Box 3207, Duke University Medical Center, Durham, North Carolina 27710, USA
    Schizophr Res 102:108-15. 2008
    ..An education-correction factor was calculated and recommended only for non-schizophrenia patients. Eight different verbal memory tests were found to have equivalent levels of difficulty...
  58. ncbi Implementation considerations for multisite clinical trials with cognitive neuroscience tasks
    Richard S E Keefe
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3270, Durham, NC 27710, USA
    Schizophr Bull 34:656-63. 2008
    ..Suggestions for overcoming these implementation challenges are offered...
  59. ncbi Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: A cross-sectional study
    Winnie W Leung
    Department of Veterans Affairs, VISN 3 Mental Illness, Research, Education and Clinical Center MIRECC, Bronx, New York, USA
    J Int Neuropsychol Soc 14:479-88. 2008
    ..The disability seen in NP normal cases indicates that factors other than cognitive impairments may determine aspects of everyday outcomes in schizophrenia...
  60. ncbi Correlates of recovery of social functioning in types I and II bipolar disorder patients
    Aliza P Wingo
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA
    Psychiatry Res 177:131-4. 2010
    ..I), co-morbid psychiatric illness, and executive functioning status. The findings are consistent with deleterious effects of even residual depressive symptoms in BPD patients...
  61. ncbi The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia
    Joseph I Friedman
    Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY 10029, USA
    J Clin Psychopharmacol 25:237-42. 2005
    ..Further research on alternative serotonergic approaches to cognitive enhancement in schizophrenia is warranted...
  62. ncbi Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study
    Philip D Harvey
    Mt Sinai School of Medicine, New York, NY, USA
    Schizophr Res 59:243-51. 2003
    ..In general, these data support the validity of cross-national neuropsychological assessments...
  63. ncbi A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia
    Joseph I Friedman
    Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY 10029, USA
    Biol Psychiatry 51:349-57. 2002
    ..An alternative treatment is the allosterically potentiating ligands, which enhance the activity of (sensitize) nicotinic receptors in the presence of acetylcholine...
  64. ncbi Structural differences within negative and depressive syndrome dimensions in schizophrenia, organic brain disease, and major depression: A confirmatory factor analysis of the positive and negative syndrome scale
    Daniel P Eisenberg
    Department of Psychiatry, Beth Israel Medical Center, New York, NY, USA
    Psychopathology 42:242-8. 2009
    ..This study tested the hypothesis that negative and depressive syndromes as measured by the Positive and Negative Syndrome Scale (PANSS) are consistent across different diagnoses...
  65. ncbi Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects
    Robert Grossman
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Ann N Y Acad Sci 1071:410-21. 2006
    ....
  66. ncbi A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder
    S Nassir Ghaemi
    Department of Psychiatry, Mood Disorders Program, Tufts Medical Center, Boston, MA, USA
    J Clin Psychopharmacol 29:291-5. 2009
    ..In addition, the effect of galantamine on clinical measures of functioning and psychopathology was assessed...
  67. ncbi Enhanced effects of cortisol administration on episodic and working memory in aging veterans with PTSD
    Rachel Yehuda
    The Traumatic Stress Studies Program, Psychiatry Department, The Mount Sinai School of Medicine, New York, NY 10468, USA
    Neuropsychopharmacology 32:2581-91. 2007
    ..The findings suggest that there may be opportunities for developing therapeutic strategies using glucocorticoids in the treatment of aging combat veterans...
  68. ncbi Working memory performance in poor outcome schizophrenia: relationship to age and executive functioning
    Susan R McGurk
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    J Clin Exp Neuropsychol 26:153-60. 2004
    ..These findings indicate that LNS may be an index of executive functioning, particularly in patients who cannot perform the WCST...
  69. ncbi Age-associated differences in cognitive performance in older community dwelling schizophrenia patients: differential sensitivity of clinical neuropsychological and experimental information processing tests
    Christopher R Bowie
    Department of Psychiatry, Mt Sinai School of Medicine, 1425 Madison Ave, 4th Floor, Box 1230, New York, NY 10029, USA
    Schizophr Res 106:50-8. 2008
    ..Tests with fixed difficulty, such as clinical NP tests, may differ in their sensitivity from tests for which parametric difficulty manipulations can be performed...
  70. ncbi Managing cognitive deficits and functioning in patients with schizophrenia
    Philip D Harvey
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    J Clin Psychiatry 68:e21. 2007
  71. ncbi Stability in schizophrenia symptoms over time: findings from the Mount Sinai Pilgrim Psychiatric Center Longitudinal Study
    Abraham Reichenberg
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Abnorm Psychol 114:363-72. 2005
    ..The results demonstrate that despite changes in the severity of symptoms in individual patients with schizophrenia, the factor structure and interrelatedness of symptoms have considerable stability over time...
  72. ncbi Three dimensions of clinical symptoms in elderly patients with schizophrenia: prediction of six-year cognitive and functional status
    Eran Chemerinski
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Schizophr Res 85:12-9. 2006
    ..J., Gur, R.C., 1991. Relations among clinical scales in schizophrenia. Am. J. Psychiatry 148, 472-478. Brown, K.W., White, T., 1992. Syndromes of chronic schizophrenia and some clinical correlates. Br. J. Psychiatry 161, pp. 317-322]...
  73. ncbi Cortical and subcortical cognitive deficits in schizophrenia: convergence of classifications based on language and memory skill areas
    Philip D Harvey
    Department of Psychiatry, Mt. Sinai School of Medicine, New York, NY 10029, USA
    J Clin Exp Neuropsychol 24:55-66. 2002
    ..These data suggest that cortical versus subcortical profiles of cognitive performance in schizophrenia are inconsistent across ability areas, and are not likely to be the result of stable structural or functional brain deficits...
  74. ncbi Cognitive and brain function in schizotypal personality disorder
    Larry J Siever
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    Schizophr Res 54:157-67. 2002
    ..Preliminary trials of catecholaminergic agents suggest that these agents may be able to improve these impaired cognitive functions...
  75. ncbi From clinical research to clinical practice: a 4-year review of ziprasidone
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 101 Woodruff Circle, Atlanta, GA 30322, USA
    CNS Spectr 10:1-20. 2005
    ..This monograph summarizes the efficacy, tolerability, and safety of oral ziprasidone in the treatment of schizophrenia, schizoaffective disorder, and bipolar mania...
  76. ncbi Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale
    Richard S E Keefe
    Neurocognitive Assessment Unit, Duke University Medical Center, Durham, NC 27710, USA
    Schizophr Bull 29:45-55. 2003
    ....
  77. ncbi Premorbid functioning and treatment response in recent-onset schizophrenia
    Jonathan Rabinowitz
    Bar Ilan University, Ramat Gan, Israel
    Br J Psychiatry 189:31-5. 2006
    ..Investigating the relationship between premorbid functioning and treatment response in schizophrenia is relevant to understanding the illness and predicting treatment outcomes...
  78. ncbi Assessment of community functioning in people with schizophrenia and other severe mental illnesses: a white paper based on an NIMH-sponsored workshop
    Alan S Bellack
    University of Maryland School of Medicine, 737 West Lombard Street, Suite 551, Baltimore, MD 21201, USA
    Schizophr Bull 33:805-22. 2007
    ..quot; This criterion is problematic because different observers and constituencies often have different opinions about what types of change are clinically important and how much change is significant...
  79. ncbi The effects of guanfacine on context processing abnormalities in schizotypal personality disorder
    Margaret M McClure
    VA VISN3 Mental Illness Research, Education, and Clinical Center, Bronx, New York 10468, USA
    Biol Psychiatry 61:1157-60. 2007
    ..This study examined the potential of guanfacine for improving context processing, a feature of working memory, in SPD...
  80. ncbi Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: evidence for specificity of relationships?
    Margaret M McClure
    Department of Veterans Affairs, VISN 3 Mental Illness Research, Education, and Clinical Center MIRECC, 130 West Kingsbridge Road Bronx, NY 10468, USA
    Schizophr Res 89:330-8. 2007
    ..This study examined the specificity of the relationships between different NP abilities and performance-based measures of social and living skills...
  81. ncbi Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial
    Nina Schooler
    Hurwich Professor, Bar Ilan University, Ramat Gan, Israel
    Am J Psychiatry 162:947-53. 2005
    ..In the long term, risperidone prevents relapse in more patients and for a longer time and also induces less abnormal movements than haloperidol...
  82. ncbi Postoperative cognitive dysfunction in patients with preoperative cognitive impairment: which domains are most vulnerable?
    Jeffrey H Silverstein
    Departments of Anesthesiology, Mount Sinai School of Medicine, New York, New York 10027 6574, USA
    Anesthesiology 106:431-5. 2007
    ....
  83. ncbi The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone
    Peter F Buckley
    Medical College of Georgia, United States
    Schizophr Res 94:99-106. 2007
    ....
  84. ncbi Pharmacological treatment of cognition in schizophrenia: an idea whose method has come
    Philip D Harvey
    Am J Psychiatry 165:163-5. 2008
  85. ncbi Context processing in schizotypal personality disorder: evidence of specificity of impairment to the schizophrenia spectrum
    Margaret M McClure
    VA VISN 3 Mental Illness Research, Education and Clinical Center, Bronx, New York 10468, USA
    J Abnorm Psychol 117:342-54. 2008
    ..These findings, which are quite similar to those previously reported in patients with schizophrenia, suggest that context processing deficits are specific to the schizophrenia spectrum and are not a reflection of overall psychopathology...
  86. ncbi Context-processing deficits in schizotypal personality disorder
    Deanna M Barch
    Department of Psychology, Washington University, Campus Box 1125, One Brookings Drive, St Louis, MO 63130, USA
    J Abnorm Psychol 113:556-68. 2004
    ..Context processing was strongly associated with working memory and selective attention performance in the SPD individuals...
  87. ncbi The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients
    Kimberley P Good
    Department of Psychiatry, Dalhousie University, Suite 9216 AJLB, 5909 Veterans Memorial Lane, Halifax, NS, Canada B3H 2E2
    Schizophr Res 68:11-9. 2004
    ..However, the relationship between the clinically rated cognitive factor and performance-based cognitive test scores has not been thoroughly examined, particularly in patients who are early in the course of illness...
  88. ncbi Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial
    Philip D Harvey
    Bar Ilan University, Ramat Gan, Israel
    Am J Psychiatry 162:1888-95. 2005
    ..Further, cognitive improvement associated with treatment with risperidone was not influenced by changes in symptoms, but that relationship was significant in haloperidol-treated patients...

Research Grants9

  1. Course of Functional Deficits in Late-Life Schizophrenia
    Philip Harvey; Fiscal Year: 2007
    ..In a much-neglected area, the study of schizophrenia in late life, this research will focus on an aspect of the illness (the course of functional status) that has been studied for 100 years, but is still not well understood. ..
  2. Validation of Measures of real-world outcome
    Philip Harvey; Fiscal Year: 2007
    ....
  3. Validation of Measures of real-world outcome
    Philip Harvey; Fiscal Year: 2009
    ....
  4. Validation of Measures of real-world outcome
    Philip D Harvey; Fiscal Year: 2010
    ....